About Uniphar Biotech
Uniphar Biotech is a Healthcare company based in Chandigarh (India) founded in 2010. It manufactures ethical drugs, offers franchises, and provides contract manufacturing services. It operates on a B2B model. Its Indian entity Uniphar Biotech Private Limited reported revenue of ₹4.85 Cr. Uniphar Biotech offers products and services including ACEBR’OPUT-100, ALGEN, AMBRODEX-A, ANSAC-P, and AZILE-500. Its focus areas include Consumer, Herbal Products, Ayurvedic and Pharmaceuticals.
Company details
Uniphar Biotech Private Limited is an ISO-certified pharmaceutical company based in India. It produces and markets a wide range of products including tablets, capsules, syrups, injectables, and Ayurvedic items. The company engages in contract manufacturing and third-party orders, while offering PCD Pharma Franchise opportunities to distributors. It emphasizes quality assurance through GMP standards and serves the healthcare industry via ethical practices and nationwide distribution networks in Chandigarh.
- Headquarters Chandigarh, India
- SectorsHealthcare
- Email••••••••
- Website unipharbiotech.com
- Legal Name Uniphar Biotech Private Limited
- Date of Incorporation 13 Sep, 2013
- Jurisdiction Chandigarh, India
- Annual Revenue₹4.85 Cr
FY 2024 · -9% YoY
- Net Profit₹12.3 Lakh
FY 2024 · 3% margin
- EBITDA₹21.4 Lakh
FY 2024 · 4% margin
Associated legal entities of Uniphar Biotech
Uniphar Biotech operates through Uniphar Biotech Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Uniphar Biotech Private Limited CIN U24232CH2013PTC034725 | Active | 13 Sep 2013 | Chandigarh, Chandigarh | ₹4.9 Cr | 4 | View details |
Products & Services of Uniphar Biotech
Uniphar Biotech offers a comprehensive portfolio of products and services, including ACEBR’OPUT-100, ALGEN, AMBRODEX-A, ANSAC-P, and AZILE-500.
Tablet for respiratory relief with Acebrophylline
Syrup for urinary alkalinization and pH balance
Cough syrup with Ambroxol for respiratory support
Pain relief tablet with Aceclofenac and Paracetamol
Antibiotic tablet for bacterial infections
Board of directors of Uniphar Biotech Private Limited (Uniphar Biotech)
Uniphar Biotech Private Limited is the primary company behind Uniphar Biotech. The board of Uniphar Biotech Private Limited currently have 4 directors; the longest-serving is Rajeev Matta, appointed in 2013. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Rajeev Matta DIN 05152655 | Director | 13 Sep 2013 | 13 yrs 1 mo | Uniphar Biotech Private Limited |
| Adesh Saini DIN 06675560 | Director | 13 Sep 2013 | 13 yrs 1 mo | Uniphar Biotech Private Limited |
| Kamna Matta DIN 06675543 | Director | 13 Sep 2013 | 13 yrs 1 mo | Uniphar Biotech Private Limited |
| Ashwani Kumar Tejpal DIN 07789379 | Director | 12 Apr 2017 | 9 yrs 6 mo | Uniphar Biotech Private Limited |
Financials of Uniphar Biotech
Figures of Uniphar Biotech Private Limited, the primary company behind Uniphar Biotech, for FY 2024. Revenue was ₹4.85 Cr (-9% year on year). Net profit was ₹12.3 Lakh (3% margin). EBITDA was ₹21.4 Lakh (4% margin). Revenue has grown at a compounded annual rate of +2% over three years and +1% over five years.
- ₹4.85 CrRevenue · FY 2024 · -9% YoY
- ₹12.3 LakhNet profit · 3% margin
- ₹21.4 LakhEBITDA · 4% margin
- ₹7.5 LakhPaid-up capital
- +2%Revenue CAGR, 3 years
- +1%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Uniphar Biotech Private Limited are on its company page.
Detailed financial statements for Uniphar Biotech
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Uniphar Biotech
Complete news archive for Uniphar Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Uniphar Biotech
Uniphar Biotech was founded in 2010.
Uniphar Biotech is headquartered in Chandigarh, India.
The primary company behind Uniphar Biotech, Uniphar Biotech Private Limited, reported revenue of ₹4.85 Cr for FY 2024, down 9% year on year.
Uniphar Biotech Private Limited is an ISO-certified pharmaceutical company based in India. It produces and markets a wide range of products including tablets, capsules, syrups, injectables, and Ayurvedic items. The company engages in contract manufacturing and third-party orders, while offering PCD Pharma Franchise opportunities to distributors. It emphasizes quality assurance through GMP standards and serves the healthcare industry via ethical practices and nationwide distribution networks in Chandigarh.
Uniphar Biotech offers ACEBR’OPUT-100, ALGEN, AMBRODEX-A, ANSAC-P, and AZILE-500.
Uniphar Biotech operates through Uniphar Biotech Private Limited.
The legal entities of Uniphar Biotech currently have 4 directors, including Ashwani Kumar Tejpal, Rajeev Matta, Adesh Saini and others.